Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Profit After Tax (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Profit After Tax for 2 consecutive years, with -$11.8 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax fell 195.58% to -$11.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$88.6 million through Dec 2025, down 95.55% year-over-year, with the annual reading at -$88.6 million for FY2025, 95.55% down from the prior year.
  • Profit After Tax hit -$11.8 million in Q4 2025 for Silence Therapeutics, up from -$21.0 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $12.3 million in Q4 2024 to a low of -$35.5 million in Q3 2024.